Johns Hopkins
Associate Professor in Pulmonary & Critical Care Medicine
Talks (57)
Air Time: 253:49:21
COVID Community Monitoring - 10
Dec 17
COVID Community Monitoring - 9
Dec 17
COVID Community Monitoring - 8
Dec 17
COVID Community Monitoring - 7
Dec 17
COVID Community Monitoring - 6
Dec 17
COVID Community Monitoring - 5
Dec 17
COVID Community Monitoring - 4
Dec 17
COVID Community Monitoring - 3
Dec 17
COVID Community Monitoring - 2
Dec 17
COVID Community Monitoring - 1
Dec 17
Long COVID & Cancer - 12
Nov 24
COVID and Cancer - 11
Nov 24
DDR proteins and COVID and targets - 10
Nov 24
COVID and other RNA viruses - 9
Nov 24
COVID & Telomere Shortening - 8
Nov 24
COVID and DNA damage - 6
Nov 24
DDR & RNA viruses - 4
Nov 24
DDR & DNA viruses - 3
Nov 24
COVID & DNA Damage Response - 1
Nov 24
12-Long COVID Advocacy
Oct 31
11-Long COVID dyspnea
Oct 31
10-Long COVID dyspnea
Oct 31
8-Long COVID Management
Oct 31
9-Long COVID & symptoms
Oct 31
7-Long COVID & Serotonin
Oct 31
6-Long COVID & Serotonin
Oct 31
5-Long COVID & ET-1
Oct 31
4-Long COVID Viral Reservoir
Oct 31
3-Long COVID, viral reservoir
Oct 31
INTRO: 13 talks on Pulm fibrosis $ COVID
Sep 24
Clinical management of ILA s/p COVID -11
Sep 24
Prevalence of Pulm Fibrosis s/p COVID-10
Sep 24
Post Viral Pulm Fibrosis -9
Sep 24
Clinical concern: post COVID fibrosis -7
Sep 24
Pulmonary Fibrosis & COVID - 6
Sep 24
Pulmonary fibrosis & Imaging - 5
Sep 24
Pulmonary fibrosis on imaging - 4
Sep 24
Immune cells & pulmonary fibrosis - 3
Sep 24
Pathology of pulmonary fibrosis- 2
Sep 24
Pulmonary Fibrosis - 1
Sep 24
Overview of COVID & ATE/VTE
Aug 29
Anticoagulation in Lactating Patients
Aug 29
Treating VTE in COVID
Aug 29
Rates of ATE/VTE in COVID19
Aug 29
COVID ATE/VTE in ICU patients
Aug 29
Clinical Management of ATE/VTE in COVID
Aug 29
COVID & Microthrombi
Aug 29
COVID & Platelet Activation
Aug 29
COVID and Thrombotic Disease
Aug 29
COVID & Endothelial Dysfunction
Aug 29
